Power your Real-World Data with AI-powered Pathology

Learn More

PathExplore

Unprecedented resolution of the tumor microenvironment (TME) from H&E, powered by AI.
PathExplore logo


PathExplore is an AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) with single-cell resolution1


Pixel-Level Analysis of Gigapixel Images


PathExplore’s underlying AI models segment, detect, and classify millions of cells across tissue regions of the entire hematoxylin and eosin (H&E) whole slide image (WSI).


HIFs – Structured, Standardized, and Scalable Analysis of the TME


Human interpretable features (HIFs) are standardized metrics that characterize the cell and tissue composition of each WSI. PathExplore delivers >600 unique HIFs per sample, including counts of cells and their spatial distribution across tissue regions, to enable streamlined and structured analysis of the TME.



 

Example Human Interpretable Features:

  • Area of Tumor Tissue
  • Total Number of Lymphocytes
  • Density of Lymphocytes in Stroma (Stromal TILs)
  • Ratio of Lymphocytes to Fibroblasts Near the Epithelial-Stromal Interface
 
Contact us today for a demo

Introducing PathExplore

Watch the Video

Robustly Trained, Trusted by Partners

>8.5 million

pathologist annotations

>100K

whole slide images

150K+

WSIs analyzed to date

50+

scientific presentations and publications


Accelerate precision oncology research by combining the accessibility of existing H&Es with the unprecedented resolution of AI


PathExplore delivers hundreds of standardized human interpretable features (HIFs) to quantitatively characterize the TME


HIFs provide structured, histopathological data to enable explorations of tumor biology at multiple scales by seamlessly linking to complementary molecular data


Dig deeper into the TME with expanded AI models including collagen and fibrosis characterization, immune phenotyping, and tertiary lymphoid structure (TLS) identification

Available across 14 cancer indications for scalable analysis across multiple development programs

PathExplore includes indication-specific features tailored to each disease's unique tumor histology, as well as indication-agnostic features that enable streamlined, pan-tumor analyses.

Proven Research and Applications

Apply

Scale research and insights across disease areas and drug programs

Identify

Identify novel histological biomarkers and drivers of therapeutic response.

Improve

Improve quantification of established biomarkers and disease signatures.

Case Study 1

Exploring Histological Features of Molecular Biomarkers


PathExplore HIFs demonstrate biologically-relevant correlations with molecular measurements of lymphocyte abundance and immune infiltration across multiple tumor types.

Tumor-infiltrating lymphocytes (TIL) play a prominent role in cancer prognosis and treatment decision-making. In a poster presented at SITC, researchers demonstrated a correlation between lymphocyte-associated Human Interpretable Features (HIFs) and established lymphocyte markers from molecular measurement (e.g. CD8A) as well as complex immune signatures (e.g., lymphocyte infiltration)
Download the full poster

Case Study 2

Discovering Novel Biomarkers


PathExplore analysis of the tumor microenvironment revealed a relationship between cell nuclear morphology and patient outcomes in high-grade serous ovarian cancer.

Manual pathology techniques can fall short in understanding the underlying disease biology of aggressive cancers. In a poster presented at ESMO, researchers uncovered a link between cancer cell nuclear size variability and overall survival, showcasing the potential of HIFs derived from H&E whole slide images as powerful predictors of patient response.
Download the full poster
nuclear morphology chart

Rapid, Scalable Deployment of PathExplore


PathExplore Data Access Program

PathAI offers academic researchers access to PathExplore's HIFs associated with publicly available H&E WSI from The Cancer Genome Atlas (TCGA). This program allows researchers to access PathExplore HIFs via our digital pathology platform AISight to use alongside existing clinical and molecular data from TCGA.

This data is free to academic researchers, and available via license for non-academic partners. To learn more and apply to the PathExplore data access program, please contact [email protected]. Non-academic researchers may additionally reach out to [email protected].
hospital staff members chatting

Resources

Download the PathExplore™ ebook

Read eight real-world applications from a growing number of research teams using AI-powered pathology solutions, including PathExplore, in the context of the below use cases:
  • Discovering novel biomarkers
  • Exploring histological features of molecular biomarkers
  • Re-envisioning approaches to biomarker testing
  • Targeting appropriate patient populations
Learn More
How AI and Digital Pathology are Shaping Drug Development

Leveraging Real-World Data for Real-World Impact

Integrate quantitative and structured pathology data with clinico-genomic real-world data sets to:
  • Discover novel histopathology biomarkers
  • Enhance clinical development and trial design
  • Assess real-world prevalence and treatment effectiveness
Learn more about Real-World Data
Real-world data graphic

Contact Us

Connect with our business development team to learn more about PathExplore.
Contact Us
Group of Path AI employees working together in a conference room with their laptops

PathExplore is for research use only. Not for use in diagnostic procedures.